 |
 |
PARKINSON'S DISEASE NEWS 31st January 2009 - New clinical trial NEW GLUTAMATE ANTAGONIST CLINICAL TRIAL RESULTS Addex Pharmaceuticals have announced what they describe as "the successful completion" of Phase I studies of a newly developed modified release formulation of ADX48621. ADX48621 is a glutamate antagonist aimed at treating the dyskinesia caused in Parkinson's Disease by taking L-dopa. The study showed that the new formulation achieved satisfactory pharmacokinetics, safety and tolerability with single and repeat dose administration across the dose range planned to be used for the Phase II proof of concept study, which is expected to start later this year. Although Addex have described the clinical trials as successful, Phase I clinical trials do not involve people with the medical disorder. So nobody with Parkinson's Disease was actually involved in the clinical trial. For the full details go to the Press release. Excessive dopamine can lead to dyskinesia, and is usually caused by taking too much L-dopa. Therefore, keeping L-dopa to sufficient rather than excessive dosages can help to reduce dyskinesia. Source: Viartis Rayilyn Brown Director AZNPF Arizona Chapter National Parkinson Foundation [log in to unmask] ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn